Class information for:
Level 1: RIVAROXABAN//DABIGATRAN//APIXABAN

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
3798 1830 36.9 81%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
1107 9272 WARFARIN//CYP2C9//VKORC1

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 RIVAROXABAN Author keyword 265 53% 19% 352
2 DABIGATRAN Author keyword 163 43% 16% 294
3 APIXABAN Author keyword 157 53% 11% 207
4 DABIGATRAN ETEXILATE Author keyword 112 74% 5% 84
5 EDOXABAN Author keyword 94 67% 5% 84
6 XIMELAGATRAN Author keyword 73 61% 4% 78
7 MELAGATRAN Author keyword 48 60% 3% 52
8 FACTOR XA INHIBITORS Author keyword 45 46% 4% 72
9 FACTOR XA INHIBITOR Author keyword 42 40% 5% 83
10 BAY 59 7939 Author keyword 37 100% 1% 14

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 RIVAROXABAN 265 53% 19% 352 Search RIVAROXABAN Search RIVAROXABAN
2 DABIGATRAN 163 43% 16% 294 Search DABIGATRAN Search DABIGATRAN
3 APIXABAN 157 53% 11% 207 Search APIXABAN Search APIXABAN
4 DABIGATRAN ETEXILATE 112 74% 5% 84 Search DABIGATRAN+ETEXILATE Search DABIGATRAN+ETEXILATE
5 EDOXABAN 94 67% 5% 84 Search EDOXABAN Search EDOXABAN
6 XIMELAGATRAN 73 61% 4% 78 Search XIMELAGATRAN Search XIMELAGATRAN
7 MELAGATRAN 48 60% 3% 52 Search MELAGATRAN Search MELAGATRAN
8 FACTOR XA INHIBITORS 45 46% 4% 72 Search FACTOR+XA+INHIBITORS Search FACTOR+XA+INHIBITORS
9 FACTOR XA INHIBITOR 42 40% 5% 83 Search FACTOR+XA+INHIBITOR Search FACTOR+XA+INHIBITOR
10 BAY 59 7939 37 100% 1% 14 Search BAY+59+7939 Search BAY+59+7939

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 FACTOR XA INHIBITOR 457 58% 29% 523
2 DIRECT THROMBIN INHIBITOR 330 59% 20% 367
3 DABIGATRAN ETEXILATE 281 56% 19% 340
4 BAY 59 7939 165 79% 6% 107
5 RIVAROXABAN 146 40% 16% 284
6 COAGULATION ASSAYS 138 69% 6% 117
7 ETEXILATE 130 60% 8% 141
8 NONVALVULAR ATRIAL FIBRILLATION 89 30% 14% 248
9 RIVAROXABAN BAY 59 7939 69 93% 1% 26
10 ORAL DIRECT THROMBIN 65 70% 3% 54

Journals

Reviews


Title Publ. year Cit. Active
references		 % act. ref.
to same field
Clinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban 2014 22 60 93%
How I treat target-specific oral anticoagulant-associated bleeding 2014 19 67 81%
Reversing the new oral anticoagulants with prothrombin complex concentrates (PCCs): what is the evidence? 2014 22 47 55%
Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development 2009 212 76 75%
Benefit-risk profile of non-vitamin K antagonist oral anticoagulants in the management of venous thromboembolism 2015 3 74 64%
The new oral anticoagulants 2010 124 31 97%
New Oral Anticoagulants Increase Risk for Gastrointestinal Bleeding: A Systematic Review and Meta-analysis 2013 50 59 68%
Reversal of anticoagulants: an overview of current developments 2015 4 50 42%
Recent Advances in the Development of Specific Antidotes for Target-Specific Oral Anticoagulants 2015 2 17 71%
Pharmacodynamic and pharmacokinetic basics of rivaroxaban 2012 36 15 100%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ.
in class
1 INT SURG THROMBOSIS FORUM 12 86% 0.3% 6
2 GLOBAL CLIN DEV MED AFFAIRS 8 70% 0.4% 7
3 PHARMACOMETRY 8 100% 0.3% 5
4 NAMUR THROMBOSIS HEMOSTASIS NTHC 6 71% 0.3% 5
5 HORSHOLM HOSP 4 67% 0.2% 4
6 PHARMA RD DISCOVERY 4 75% 0.2% 3
7 CLIN CARDIOL ANGIOL 1 3 100% 0.2% 3
8 SPINE CLINCLIN TRIAL UNIT 3 100% 0.2% 3
9 ANTITHROMBOSIS 3 33% 0.4% 8
10 VASC MED HEMOSTASIS 3 50% 0.2% 4

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000220207 ATRIAL FIBRILLATION//WARFARIN//CITY HOSP
2 0.0000195029 PROTHROMBIN COMPLEX CONCENTRATE//PROTHROMBIN COMPLEX CONCENTRATES//ANTICOAGULATION REVERSAL
3 0.0000115116 RESIDUAL THROMBOSIS//RECURRENT VENOUS THROMBOEMBOLISM//ANTICOAGULANT RELATED BLEEDING
4 0.0000111796 THROMBOPROPHYLAXIS//VENOUS THROMBOEMBOLISM//DEEP VEIN THROMBOSIS
5 0.0000097758 THROMBIN GENERATION//SYN SE BV//PHYS BIOCHEM BLOOD
6 0.0000096598 HIRUDIN//FACTOR XA//THROMBIN INHIBITOR
7 0.0000061503 LOW MOLECULAR WEIGHT HEPARIN//UNFRACTIONATED HEPARIN//ANTI XA ACTIVITY
8 0.0000058435 BRIDGING ANTICOAGULATION//BRIDGING THERAPY//BLOOD THINNERS
9 0.0000054243 HEPARIN INDUCED THROMBOCYTOPENIA//ARGATROBAN//LEPIRUDIN
10 0.0000052977 INTERNATIONAL SENSITIVITY INDEX//PROTHROMBIN TIME//INTERNATIONAL NORMALIZED RATIO